Mundipharma International Corp. Ltd., of Singapore, announced its planned distribution of Medifoam in China starting early 2015, marking a key milestone in the company's plan to rapidly expand the wound dressing product's reach in East Asia and South East Asia. Read More
Amarantus Bioscience Holdings Inc., of San Francisco and Geneva, reported top-line data from a 140-subject LP-002 study, demonstrating that multiple individual biomarkers achieved statistically significant results to correctly identify patients with Alzheimer's disease from healthy control using the company's Lympro Test, a lymphocyte proliferation diagnostic. Read More
Oncomed Pharmaceuticals Inc., of Redwood City, Calif., enrolled the first biomarker-selected patient in its anti-Notch1 antibody phase Ia solid tumor clinical trial, triggering a $5 million milestone payment from partner Glaxosmithkline plc, of London. Read More
Aldeyra Therapeutics Inc., of Lexington, Mass., closed a $7.79 million private placement of common stock and warrants led by Perceptive Advisors LLC, with participation by Knoll Capital, Sphera Global Healthcare Fund, DAFNA Capital and other accredited investors. Read More
An internationally sponsored report has called for a new culture to make the open sharing of clinical trials data the norm, saying there is an unprecedented opportunity to advance the world's health by doing so. Read More
HONG KONG — A member of a new class of small-molecule drugs has proved to be an attractive candidate for lead optimization in the search for new drugs for the treatment of tuberculosis (TB), researchers from the Novartis Institute for Tropical Diseases (NITD) in Singapore reported in the Jan. 7, 2015, issue of Science Translational Medicine. Read More
SAN FRANCISCO – Immune Design Corp. CEO Carlos Paya told attendees at the J.P. Morgan Healthcare Conference Thursday that the company is making solid progress toward what he believes is the future of in vivo cancer immunotherapy: combining the company's tumor-specific cytotoxic T cells (CTL)-boosting therapy CMB305 with a checkpoint inhibitor. Read More
SAN FRANCISCO – Last year saw the rise and fall of tax inversions as a big-pharma strategy, rather speedily quashed by the U.S. Treasury Department but useful for some before the party ended. Read More
SAN FRANCISCO – A week after disclosing the successful completion of an initial research goal and extending its partnership with Evotec AG, newco Padlock Therapeutics Inc. landed at the 33rd Annual J.P. Morgan (JPM) Healthcare Conference with its veteran CEO juggling "a full dance card" of partnering meetings. Read More
If numbers are anything to go by, 2014 was the year of the biologic. Nearly a fourth of the 41 novel drugs the FDA approved last year were biologics. Read More
